Abstract
Background Respiratory syncytial virus (RSV) infection has been associated with childhood wheeze and asthma, and potential mechanisms include persistent epigenetic effects.
Methods In the randomized, placebo-controlled MAKI trial, 429 preterm infants randomly received RSV immunoprophylaxis with palivizumab or placebo during their first RSV season. Children were followed until age 6 for asthma evaluation. DNA methylation in cells obtained by nasal brushes at age 6 was measured by Illumina MethylationEPIC array.
Results RSV immunoprophylaxis in infancy had significant impact on global methylation patterns in nasal cells at age 6. The first principal component related to the immunoprophylaxis intervention was enriched for the pathway “positive regulation of defense response to virus by host” and “antigen processing and presentation” and driven by methylation changes in NOD2, DGKG, MSH3, and ITPR2. Three CpGsites, cg18040241, cg08243963, cg19555973 were differentially methylated at genome-wide significance, but were not associated with asthma. Differential methylation region analysis identified regions near genes that were previously implicated in the development of asthma and allergy such as HLA-DPA1, HLA-DPB1, FASLG, and CHI3L1.
Conclusions The study provides the first proof of concept that RSV immunoprophylaxis during infancy has long-term effects on nasal epigenetic signatures at age 6, relating to host antiviral defense pathways.
Competing Interest Statement
This study was supported by a grant from MedImmune to LJB and GHK. Funders had no role in design, interpretation and reporting of this study. L.J.B. reports grants from AbbVie during the conduct of the study and grants from MedImmune, Janssen, MeMed, and the Bill & Melinda Gates Foundation. None of the other authors report competing interests relating to the work presented in this manuscript.
Clinical Trial
ISRCTN73641710
Funding Statement
This study was supported by MedImmune grant ESR-14-10006
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The MAKI study was approved by the ethical committee Medisch Ethische Toetsingscommissie (METC) of the Universitair Medisch Centrum Utrecht, 21/07/2008.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The epigenetic datasets generated and analyzed are available from the corresponding author on reasonable request.
Abbreviations
- RSV
- Respiratory syncytial virus;
- EWAS
- Epigenome-wide association studies;
- PCA
- Principal components analysis;
- NMDS
- Nonmetric multidimensional scaling;
- DMR
- Differential methylation region;
- ESCRT
- Endosomal sorting complexes required for transport.
